|
Activity Number:
|
352
- Small Area Estimation, Analysis of Complex Sample Survey Data, and New Advances for Health Surveys
|
|
Type:
|
Contributed
|
|
Date/Time:
|
Thursday, August 12, 2021 : 10:00 AM to 11:50 AM
|
|
Sponsor:
|
Survey Research Methods Section
|
|
Abstract #318765
|
|
|
Title:
|
COVID-19 Vaccine Effects on Seroprevalence
|
|
Author(s):
|
Richard Lee Harding* and Ronaldo Iachan and Adam Lee and Yangyang Deng and Tonja Kyle and Myrna Charles and Ryan Wiegand
|
|
Companies:
|
ICF and ICF and ICF and ICF and ICF and CDC and CDC
|
|
Keywords:
|
COVID-19;
Seroprevalence Rate;
Vaccination Data
|
|
Abstract:
|
The first COVID-19 vaccines were given in December 2020 in the U.S. Vaccine administration has increased at various rates for different groups. After SARS-CoV-2 infection, persons develop anti-N and anti-S protein antibodies. The current vaccines only contain the S spike protein and vaccinated persons only develop anti-S antibodies. Depending on the assays used, seroprevalence estimates may measure either antibodies to the spike protein or antibodies induced by natural infection only. Our analyses uses these measurements to distinguish between the two levels of antibody prevalence. We use weighted data from our repeated, cross-sectional seroprevalence study of national laboratory serologic testing to assess the effects of vaccines on the prevalence of antibodies. Our dataset merged vaccination data with biweekly seroprevalence data by county. We develop piecewise regression mixed models that detect points in time when jumps can be observed in seroprevalence rates across rounds. By merging county data from the ACS, our multilevel models for seroprevalence indicators will control for demographic and socio-economic traits in assessing the impact of county-level vaccination rates.
|
Authors who are presenting talks have a * after their name.
